Non-small cell lung cancer research: advances and persistent challenges

Area of Science:

• Oncology
• Precision Medicine
• Cancer Therapeutics

Background:

• Non-small cell lung cancer (NSCLC) is a major cause of cancer mortality.
• Recent progress includes antibody-drug conjugates (ADCs) and next-generation tyrosine kinase inhibitors (TKIs).
• Immunotherapy and advanced diagnostics like liquid biopsy are also evolving.

Purpose of the Study:

• To review recent advancements in NSCLC therapeutics and diagnostics.
• To identify persistent challenges in treatment efficacy and implementation.
• To outline future directions for improving NSCLC patient outcomes.

Main Methods:

• Review of current literature on NSCLC therapies, including ADCs and TKIs.
• Analysis of emerging diagnostic tools such as liquid biopsy and AI-based histopathology.
• Discussion of challenges including acquired resistance, biomarker limitations, and implementation barriers.

Main Results:

• Promising efficacy of TROP-2-targeting ADCs and HER3-DXd in refractory NSCLC.
• Improved outcomes with novel TKIs for oncogene-driven NSCLC.
• Advancements in immunotherapy and diagnostics enhance personalization but face validation hurdles.

Conclusions:

• Overcoming acquired resistance and improving biomarker utility are critical.
• Streamlining comprehensive genomic profiling (CGP) and addressing data gaps for special populations are essential.
• Combination strategies, ADCs, AI, and ctDNA hold promise for future NSCLC management.